Navigation Links
Preclinical Efficacy Data Demonstrate Ability of Tengion's Neo-Bladder Augment to Restore Bladder Function
Date:10/29/2007

Exhibition in San Francisco, California.

About the Tengion Neo-Bladder Augment(TM)

Tengion's most advanced regenerative medicine program is the autologous Tengion Neo-Bladder Augment. There are currently two Phase 2 clinical trials ongoing evaluating the Neo-Bladder Augment: one in pediatric patients with neurogenic bladder due to spina bifida, and the other in adult patients with neurogenic bladder due to spinal cord injuries. The Neo-Bladder Augments for both Phase 2 clinical trials are being developed at Tengion's state-of-the-art manufacturing facility using cells taken from a small biopsy of each patient's bladder. Each Neo-Bladder Augment consists of a biodegradable scaffold seeded with cells cultured by Tengion scientists from the patient's own (i.e., autologous) healthy cells. A surgeon implants the Neo-Bladder Augment in the patient's body, where it is designed to harness the body's inherent regenerative capabilities resulting in a regenerated bladder with improved functionality.

About Tengion

Tengion Inc., a clinical stage biotechnology company, is a leader in developing autologous neo-organs and tissues, such as bladders, that are derived from the patient's own (autologous) cells. Tengion's proprietary approach to regenerative medicine has the potential to enable people with organ and tissue failure to lead healthier lives without donor transplants or the side effects of current therapies. Headquartered in East Norriton, PA, Tengion also has research and pilot manufacturing facilities located in Winston-Salem, NC. For more information, visit Tengion online at: http://www.tengion.com.


'/>"/>
SOURCE Tengion, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Reforming FDA: Focus on safety, let market judge efficacy
2. Chemical Stability of Disposables
3. Chemical Stability of the Brinkmann Bottletop Dispenser and the Brinkmann Bottletop Buret
4. Cell Proliferation and Viability Measurement
5. Rapid hit confirmation and early hERG liability testing using the IonWorks HT system
6. DNA Stability with Oragene
7. FluoroMax multiwavelength capability
8. Near IR capability of the FluoroLog
9. LIVE/DEAD Viability/Cytotoxicity Assay for Animal Cells Using the SpectraMax Gemini XS Fluorescence Microplate Reader (MaxLine Application Note #43)
10. The Affymetrix GeneChip Scanner 3000 New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range
11. Promegas Multiplexed Cell Viability and Apoptosis Assays performed on the PHERAstar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... 2015 , ... Sterlitech Corporation introduces the compact, quiet, and ... laboratory equipment. With optimized features, such as PTFE-coated contact surfaces, an oil-free design, ... solution for a broad range of vacuum filtration applications. , Featuring a 1/7 ...
(Date:7/30/2015)... ... ... Ralco is honored to announce that it is the primary sponsor of the ... in Marshall. The Ralco Enrichment Center is an interactive experience where the public can ... lives. This unique exhibit also features a birthing center for fair goers to watch ...
(Date:7/30/2015)... -- According to a new market research ... PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), by ... End Users - Global Forecast to 2020", published by ... 2,107.99 million by 2020 from USD 1,034.93 million in ... Browse more than 75 market ...
(Date:7/30/2015)... 30, 2015 Ascendis Pharma A/S (Nasdaq: ... its innovative TransCon technology to address significant unmet ... a six-month Phase 2 study to evaluate the ... in 53 treatment-naïve, pre-pubertal children with growth hormone ... pleased with the top-line results from our Phase ...
Breaking Biology Technology:Sterlitech Launches New Line of Vacuum Pumps 2Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... Mich., July 8 GeneGo, Inc., the leading,systems biology ... GeneGo products. Unilever uses systems analysis tools for,research in ... "Unilever was one of GeneGo,s first customers in Europe, ... said Julie Bryant, GeneGo,s VP,of Business development. "Unilever is ...
... Metabolex, Inc., a,biopharmaceutical company focused on the ... treatment of metabolic diseases,announced that it has promoted ... and Robert Martin to Vice President of Project ... development in our company,in support of our expanding ...
... Md., July 7 ActiPatch(TM), the,product marketed by Bioelectronics ... and the way we heal. Recently chosen as "One ... MedicalHeadway.com,ActiPatch is fast becoming the treatment of choice for ... decision to include ActiPatch in the top 9 medical ...
Cached Biology Technology:Unilever Extends Their GeneGo MetaCore License 2Metabolex Names Zhao, Martin to Executive Posts 2BioElectronic's ActiPatch(TM) Product Chosen as 'One of 9 Medical Breakthroughs That May Change Your Life' 2BioElectronic's ActiPatch(TM) Product Chosen as 'One of 9 Medical Breakthroughs That May Change Your Life' 3BioElectronic's ActiPatch(TM) Product Chosen as 'One of 9 Medical Breakthroughs That May Change Your Life' 4
(Date:7/23/2015)... Inc. (NASDAQ: AWRE ), a leading supplier of biometrics ... quarter ended June 30, 2015.  Revenue for ... of 33% compared to $6.8 million in the same quarter ... was $0.3 million, or $0.01 per diluted share, which compared ... same period a year ago.  Lower revenue ...
(Date:7/21/2015)... , July 21, 2015 Today, ZTE announced ... received as well as expected revenues in 2015 that relate to ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ... a leading smartphone manufacturer in China and ... 02 5 for Axon , ...
(Date:7/21/2015)... NEW YORK , July 21, 2015 /PRNewswire/ ... critical systems, as seen in the recent U.S. ... enterprises a solution to the infosec conundrum, but ... data is stored. To address this dilemma, Biometrics-as-a-Service ... of its Biometric Tokenization SDK for third party ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4
... and ecological sustainability of biofuels and the impact of ... America will take place on Friday, Dec. 5, in ... Neotropical Forests: Trends, Implications and Emerging Alternatives, is sponsored ... the Program in Native Species Reforestation, both joint programs ...
... Associated Professor, DSc Barbara Ann Halkier, Department of ... Life Sciences, University of Copenhagen, has been granted ... award for her excellent research into secondary metabolites, ... plants. In particular, her research has focused ...
... Company Experiences Record Revenue Growth from Operations in Third Quarter , ... bioMETRX, Inc. (OTC Bulletin Board: BMRX), a leading developer of consumer-based ... ending September 30, 2008. , , ... 430% increase over second quarter revenues of $100,000. , ...
Cached Biology News:Conference to explore sustainability of biofuels 2The Danisco Award 2008 goes to D.Sc. Barbara Ann Halkier from Faculty of Life Sciences, Copenhagen 2bioMETRX, Inc. Highlights 3rd Quarter 2008 Financial Results 2